Summary

Global HIV Drugs Market is valued at approximately USD 34.28 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.5% over the forecast period 2024-2032. Human immunodeficiency virus (HIV) is a chronic and life-threatening disease, which can be transferred from one person to another through blood-to-blood and sexual contact. It attacks immune cells known as CD-4 cells, making the body susceptible to infections and other diseases. Over the years, the rise in prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs, which help to prevent the multiplication of the HIV virus, thereby reducing the risk of its transmission. The growth of the HIV drugs market is driven by the rising demand for HIV medications, increased initiatives by various government associations to raise awareness about the diagnosis and management of HIV, and a rise in cases of HIV. For instance, according to the Joint United Nations Program on HIV and AIDS (UNAIDS), 39 million people globally were living with HIV in 2022. Additionally, 1.3 million people became newly infected with HIV, and 630,000 people died from AIDS-related illnesses in the same year.
However, lack high cost of HIV treatment, along with the social stigma and discrimination are the key factors that are substantially halting the growth of the market globally. The pharmaceutical industry continues to invest in research and development efforts to better understand the underlying mechanisms of HIV and develop innovative therapies. This includes exploring new drug targets, conducting clinical trials, and investigating combination therapies. Therefore, the rise in R&D in drug discovery drives the growth of the HIV drugs market size during the forecast period. For instance, in February 2023, Merck & Co., Inc. announced the opening of enrollment in its new Phase 3 clinical program with investigational once-daily islatravir 0.25 mg in combination with doravirine 100 mg (DOR/ISL) for the treatment of HIV-1 infection.
Furthermore, the rise in awareness about HIV leads to more individuals seeking testing and diagnosis. This results in the identification of previously undiagnosed cases, subsequently increasing the demand for HIV drugs to initiate treatment. For instance, the U.S. Agency for International Development and various associations globally have introduced many initiatives and education campaigns for community awareness to address HIV prevention, treatment, and care.
The key regions considered for the global HIV drugs Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America accounted for a major HIV drugs market share in 2023 and is expected to maintain its dominance during the forecast period. The presence of several major players, rise in the number of clinical trials of HIV drugs, availability of advanced healthcare facilities, and high healthcare expenditure from government organizations in the region drive market growth. Whereas, Asia-Pacific is expected to grow at the highest rate during the forecast period. This is attributable to a rise in cases of HIV, as well as an increase in the purchasing power of populated countries such as China and India. The region possesses a huge population base, with China and India being the first and second most populated countries, respectively. A rise in population along with longer life expectancy is expected to drive market growth in Asia-Pacific during the forecast period.

Major market players included in this report are:
GlaxoSmithKline plc
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Cipla Ltd.
Merck & Co., Inc.
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
AbbVie Inc.
Boehringer Ingelheim International GmbH
Teva Pharmaceutical Industries Ltd.
The detailed segments and sub-segment of the market are explained below:
By Medication Class:
• Multi-Class Combination Drugs
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Protease Inhibitors (PIs)
• Entry Inhibitors
• HIV Integrase Strand Transfer Inhibitors
• Others
By Distribution Channel:
• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Pharmacies
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
Latin America
• Brazil
• Mexico
• RoLA
Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. Global HIV Drugs Market Executive Summary
1.1. Global HIV Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Medication Class
1.3.2. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global HIV Drugs Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global HIV Drugs Market Dynamics
3.1. Market Drivers
3.1.1. Rise in Demand for HIV Drugs
3.1.2. Increase in Initiatives to Raise Awareness about HIV
3.1.3. Increase in Cases of HIV
3.2. Market Challenges
3.2.1. High Cost of HIV Treatment
3.2.2. Social Stigma and Discrimination
3.3. Market Opportunities
3.3.1. Rise in R&D in Drug Discovery
3.3.2. Increase in Awareness about HIV
3.3.3. Rise in Funding for HIV Awareness and Treatment

Chapter 4. Global HIV Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global HIV Drugs Market Size & Forecasts by Medication Class 2022-2032
5.1. Segment Dashboard
5.2. Global HIV Drugs Market: Medication Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Multi-Class Combination Drugs
5.2.2. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
5.2.3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.2.4. Protease Inhibitors (PIs)
5.2.5. Entry Inhibitors
5.2.6. HIV Integrase Strand Transfer Inhibitors
5.2.7. Others

Chapter 6. Global HIV Drugs Market Size & Forecasts by Distribution Channel 2022-2032
6.1. Segment Dashboard
6.2. Global HIV Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Hospital Pharmacies
6.2.2. Drug Stores and Retail Pharmacies
6.2.3. Online Pharmacies

Chapter 7. Global HIV Drugs Market Size & Forecasts by Region 2022-2032
7.1. North America HIV Drugs Market
7.1.1. U.S. HIV Drugs Market
7.1.1.1. Medication Class breakdown size & forecasts, 2022-2032
7.1.1.2. Distribution Channel breakdown size & forecasts, 2022-2032
7.1.2. Canada HIV Drugs Market
7.2. Europe HIV Drugs Market
7.2.1. U.K. HIV Drugs Market
7.2.2. Germany HIV Drugs Market
7.2.3. France HIV Drugs Market
7.2.4. Spain HIV Drugs Market
7.2.5. Italy HIV Drugs Market
7.2.6. Rest of Europe HIV Drugs Market
7.3. Asia-Pacific HIV Drugs Market
7.3.1. China HIV Drugs Market
7.3.2. India HIV Drugs Market
7.3.3. Japan HIV Drugs Market
7.3.4. Australia HIV Drugs Market
7.3.5. South Korea HIV Drugs Market
7.3.6. Rest of Asia Pacific HIV Drugs Market
7.4. Latin America HIV Drugs Market
7.4.1. Brazil HIV Drugs Market
7.4.2. Mexico HIV Drugs Market
7.4.3. Rest of Latin America HIV Drugs Market
7.5. Middle East & Africa HIV Drugs Market
7.5.1. Saudi Arabia HIV Drugs Market
7.5.2. South Africa HIV Drugs Market
7.5.3. Rest of Middle East & Africa HIV Drugs Market

Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.1.1. Company 1
8.1.2. Company 2
8.1.3. Company 3
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. GlaxoSmithKline plc
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Johnson & Johnson
8.3.3. Gilead Sciences, Inc.
8.3.4. F. Hoffmann-La Roche Ltd.
8.3.5. Cipla Ltd.
8.3.6. Merck & Co., Inc.
8.3.7. Bristol-Myers Squibb Company
8.3.8. AbbVie Inc.
8.3.9. Boehringer Ingelheim International GmbH
8.3.10. Teva Pharmaceutical Industries Ltd.

Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes